Formulary E-news :
Having trouble viewing this e-mail? Click here. 		You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Formulary E-news
Modern Medicine Network
 
 
 
 
 
TOP SEARCHES: Saxagliptin // Golimumab // Depression
In this issue
• Ticagrelor vs clopidogrel
• Medication intervention tools
• Perioperative fluvastatin
• Cardiometabolic disorders
Key Topic Updates

Survey

This month we would like to know...

Is your healthcare organization prepared for H1N1?

Vote in our survey, and see what other P&T committee members have to say.
Click here to vote

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

September 15, 2009
Ticagrelor associated with lower rate of death from vascular causes, MI, and stroke
In the Study of Platelet Inhibition and Patient Outcomes (PLATO) published in the New England Journal of Medicine, patients with acute coronary syndrome (ACS) who were treated with ticagrelor had significant reductions in the rate of death from vascular causes, myocardial infarction (MI), or stroke and no significant increase in the rate of overall major bleeding versus patients treated with clopidogrel. More...
Medication interventions get a boost from a powerful tool
Pharmacists can improve patient outcomes by following 3 major functions: identification of potential and actual medication-related problems (MRPs), resolution of actual MRPs, and prevention of potential MRPs. The best way to achieve these goals is through accurate documentation, and one of the chief obstacles to this is time—or rather the lack of it. Various software programs have been developed to help pharmacists reduce time spent identifying opportunities for interventions. More...
Perioperative fluvastatin treatment associated with improved CV outcome after noncardiac vascular surgery
In the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography III (DECREASE III) trial published in the New England Journal of Medicine, patients undergoing noncardiac vascular surgery who were treated with perioperative fluvastatin demonstrated a lower incidence of myocardial ischemia than patients treated with placebo. More...
P&T considerations in fashioning a knowledge base, action plan for cardiometabolic disorders and weight
Almost 25% of US adults have a constellation of abnormalities constituting cardiometabolic disorders and weight, which include central adiposity, elevated triglycerides, low levels of high-density lipoprotein, hypertension, and elevated blood glucose levels. The public health impact is clear when one considers that 38.9% of US adults report a prescription drug expense for a cardiovascular agent and 28.9% report similar expenses for metabolic agents. The P&T committee is uniquely positioned to provide knowledge and strategies to improve the treatment of patients with these conditions. More...
Key Topic Updates
Medication Safety
Mycophenolic acid associated with increased risk of pure red cell aplasia
FDA issues early communication about ongoing safety review of orlistat
Etravirine associated with severe skin and hypersensitivity reactions
Leukotriene inhibitors associated with neuropsychiatric events
Long-term tamoxifen use linked to ER-positive breast cancer
Drug Pipeline/Clinical Updates
H1N1 vaccines appear safe for adults, children
Scant evidence of combination lipid therapy benefit found
Nadroparin may prevent blood clots during chemotherapy
Bleeding rates assessed in elderly patients with AF who are taking warfarin
Guideline reduces antibiotics usage, adverse drug effects
Regulatory/Legislative
September 26 rollback of wholesale drug prices approaching fast
State privacy laws deter EHR adoption in hospitals
Use of telehealth could save billions
Global health concerns generate new therapies for home and abroad
Insurance exchanges key to expanding coverage

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.